WallStSmart

Concentra Group Holdings Parent, Inc. (CON)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 2515% more annual revenue ($56.58B vs $2.16B). NVS leads profitability with a 23.9% profit margin vs 7.7%. CON trades at a lower P/E of 17.4x. CON earns a higher WallStSmart Score of 59/100 (C).

CON

Buy

59

out of 100

Grade: C

Growth: 8.0Profit: 7.0Value: 7.7Quality: 4.8
Piotroski: 2/9

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CONUndervalued (+66.5%)

Margin of Safety

+66.5%

Fair Value

$72.22

Current Price

$22.47

$49.75 discount

UndervaluedFair: $72.22Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CON4 strengths · Avg: 9.0/10
Return on EquityProfitability
48.1%10/10

Every $100 of equity generates 48 in profit

EPS GrowthGrowth
60.1%10/10

Earnings expanding 60.1% YoY

P/E RatioValuation
17.4x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

CON2 concerns · Avg: 3.0/10
Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CON

The strongest argument for CON centers on Return on Equity, EPS Growth, P/E Ratio. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : CON

The primary concerns for CON are Profit Margin, Piotroski F-Score.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

CON profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

CON is growing revenue faster at 15.9% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CON scores higher overall (59/100 vs 51/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concentra Group Holdings Parent, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company that specializes in acquiring and managing businesses in high-growth sectors such as healthcare, technology, and infrastructure. With a commitment to operational excellence and innovation, Concentra leverages its seasoned leadership team to enhance portfolio performance through strategic investments and proactive management. This forward-looking approach positions the company to effectively capitalize on emerging trends and opportunities, making it an attractive investment for institutional investors aiming to diversify into high-potential industries.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?